| 1. |
- Ruilope, LM, et al.
(författare)
-
Design and Baseline Characteristics of the Finerenone in Reducing Cardiovascular Mortality and Morbidity in Diabetic Kidney Disease Trial
- 2019
-
Ingår i: American journal of nephrology. - : S. Karger AG. - 1421-9670 .- 0250-8095. ; 50:5, s. 345-356
-
Tidskriftsartikel (refereegranskat)abstract
- <b><i>Background:</i></b> Among people with diabetes, those with kidney disease have exceptionally high rates of cardiovascular (CV) morbidity and mortality and progression of their underlying kidney disease. Finerenone is a novel, nonsteroidal, selective mineralocorticoid receptor antagonist that has shown to reduce albuminuria in type 2 diabetes (T2D) patients with chronic kidney disease (CKD) while revealing only a low risk of hyperkalemia. However, the effect of finerenone on CV and renal outcomes has not yet been investigated in long-term trials. <b><i>Patients and</i></b> <b><i>Methods:</i></b> The Finerenone in Reducing CV Mortality and Morbidity in Diabetic Kidney Disease (FIGARO-DKD) trial aims to assess the efficacy and safety of finerenone compared to placebo at reducing clinically important CV and renal outcomes in T2D patients with CKD. FIGARO-DKD is a randomized, double-blind, placebo-controlled, parallel-group, event-driven trial running in 47 countries with an expected duration of approximately 6 years. FIGARO-DKD randomized 7,437 patients with an estimated glomerular filtration rate ≥25 mL/min/1.73 m<sup>2</sup> and albuminuria (urinary albumin-to-creatinine ratio ≥30 to ≤5,000 mg/g). The study has at least 90% power to detect a 20% reduction in the risk of the primary outcome (overall two-sided significance level α = 0.05), the composite of time to first occurrence of CV death, nonfatal myocardial infarction, nonfatal stroke, or hospitalization for heart failure. <b><i>Conclusions:</i></b> FIGARO-DKD will determine whether an optimally treated cohort of T2D patients with CKD at high risk of CV and renal events will experience cardiorenal benefits with the addition of finerenone to their treatment regimen. Trial Registration: EudraCT number: 2015-000950-39; ClinicalTrials.gov identifier: NCT02545049.
|
|
| 2. |
- Efrati, S., et al.
(författare)
-
Intrusion of coastal waters into the pelagic eastern Mediterranean : in situ and satellite-based characterization
- 2013
-
Ingår i: Biogeosciences. - : Copernicus GmbH. - 1726-4170 .- 1726-4189. ; 10:5, s. 3349-3357
-
Tidskriftsartikel (refereegranskat)abstract
- A combined dataset of near-real-time multi-satellite observations and in situ measurements from a high-resolution survey is used for characterizing physical-biogeochemical properties of a patch stretching from the coast to the open sea in the Levantine Basin (LB) of the eastern Mediterranean (EM). Spatial analysis of the combined dataset indicates that the patch is a semi-enclosed system, bounded within the mixed layer and separated from ambient waters by transport barriers induced by horizontal stirring. As such, the patch is characterized by physical-biogeochemical properties that significantly differ from those of the waters surrounding it, with lower salinity and higher temperatures, concentrations of silicic acid and chlorophyll a, and abundance of Synechococcus and picoeukaryote cells. Based on estimates of patch dimensions (similar to 40 km width and similar to 25m depth) and propagation speed (similar to 0.09ms(-1)), the volume flux associated with the patch is found to be on the order of 0.1 Sv. Our observations suggest that horizontal stirring by surface currents is likely to have an important impact on the ultra-oligotrophic Levantine Basin ecosystem, through (1) transport of nutrients and coastally derived material, and (2) formation of local, dynamically isolated niches. In addition, this work provides a satellite-based framework for planning and executing high-resolution sampling strategies in the interface between the coast and the open sea.
|
|
